2023
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
O'Donnell P, Rosenberg J, Hoimes C, Petrylak D, Milowsky M, McKay R, Srinivas S, Friedlander T, Ramamurthy C, Bilen M, Burgess E, Mar N, Moon H, Geynisman D, George S, Carret A, Yu Y, Guseva M, Moreno B, Flaig T. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K. Journal Of Clinical Oncology 2023, 41: 499-499. DOI: 10.1200/jco.2023.41.6_suppl.499.Peer-Reviewed Original ResearchLiver metastasesDay 1Disease sitesPD-L1 expression statusBlinded independent central reviewAppropriate dose modificationCisplatin-ineligible patientsManageable safety profileMetastatic urothelial cancerObjective response rateECOG PS scorePhase 3 trialPre-specified subgroupsPrimary disease siteDuration of responseIndependent central reviewMetastatic disease sitesHigh unmet needECOG PSMedian DoRRECIST v1.1Untreated LAOverall cohortPrimary endpointSecondary endpoints
2019
External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
Halabi S, Dutta S, Araujo J, Logothetis C, Sternberg C, Armstrong A, Carducci M, Chi K, De Bono J, Petrylak D, Fizazi K, Higano C, Small E, Kelly W. External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2019, 37: 5022-5022. DOI: 10.1200/jco.2019.37.15_suppl.5022.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPrognostic risk groupsMedian overall survivalOverall survivalRisk groupsPrognostic modelCastration-resistant prostate cancerECOG performance statusOpioid analgesic usePhase III trialsHigh groupTime-dependent areaAnalgesic useIII trialsPerformance statusProstate cancerRisk scoreTreatment groupsDisease sitesSpecific subgroupsMonthsCharacteristic curveSimilar resultsMenExternal validation
2018
Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.
Drakaki A, Kirby C, Van Der Heijden M, Petrylak D, Powles T, Chi K, Flechon A, Necchi A, Geczi L, Lee J, Gakis G, Bracarda S, Chowdhury S, Lin C, Keizman D, Vaishampayan U, Liepa A, Zimmermann A, Bell-McGuinn K, Castellano D. Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial. Journal Of Clinical Oncology 2018, 36: 434-434. DOI: 10.1200/jco.2018.36.6_suppl.434.Peer-Reviewed Original ResearchPlatinum-refractory metastatic urothelial carcinomaImmune checkpoint inhibitorsMetastatic urothelial carcinomaObjective response ratePrior immune checkpoint inhibitorsLiver metastasesPD-L1Subgroup analysisDouble-blinded phase 3 trialPD-1/PD-L1Disease sitesHigher objective response ratePre-specified subgroup analysisInvestigator-assessed PFSImmune checkpoint inhibitionProgression-free survivalPhase 3 trialPrespecified subgroup analysisPlatinum-based chemotherapyFrequency of gradeICI therapyMedian PFSSecondary endpointsCheckpoint inhibitorsData cutoff